Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma

PURPOSE: Elotuzumab plus pomalidomide/dexamethasone (E-Pd) demonstrated efficacy and safety in relapsed and refractory multiple myeloma (RRMM). The clinical pharmacology of elotuzumab [± lenalidomide/dexamethasone (Ld)] was characterized previously. These analyses describe elotuzumab population phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Ide, Takafumi, Osawa, Mayu, Sanghavi, Kinjal, Vezina, Heather E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739320/
https://www.ncbi.nlm.nih.gov/pubmed/34825942
http://dx.doi.org/10.1007/s00280-021-04365-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739320/
https://www.ncbi.nlm.nih.gov/pubmed/34825942
http://dx.doi.org/10.1007/s00280-021-04365-4

Ejemplares similares